FAKTOR-OPTIONSSCHEIN - ARCS BIOS Stock

Certificat

DE000MG3DE54

Market Closed - Börse Stuttgart 03:03:01 2024-06-14 pm EDT
6.45 EUR -22.85% Intraday chart for FAKTOR-OPTIONSSCHEIN - ARCS BIOS
Current month-38.75%
1 month-6.52%
Date Price Change
24-06-14 6.45 -22.85%
24-06-13 8.36 +5.29%
24-06-12 7.94 -8.84%
24-06-11 8.71 +2.83%
24-06-10 8.47 -2.19%

Delayed Quote Börse Stuttgart

Last update June 14, 2024 at 03:03 pm EDT

More quotes

Static data

Product typeExotic Products
Buy / SellCALL
Underlying ARCUS BIOSCIENCES, INC.
Issuer Morgan Stanley
WKN MG3DE5
ISINDE000MG3DE54
Date issued 2024-04-30
Strike 22.67 $
Maturity Unlimited
Parity 0.81 : 1
Emission price 10
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 10.59
Lowest since issue 6.08
Spread 0.1
Spread %1.51%

Company Profile

Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company developing differentiated molecules and combination therapies for people with cancer. The Company involves in a portfolio of investigational products, which are in clinical development with its advanced molecule, an anti-TIGIT antibody targeting lung and gastrointestinal cancers. The Company has approximately seven clinical programs that are focused on targets, including TIGIT, PD-1, adenosine A2a and A2b receptors, CD73, CD39, HIF-2a, and AXL. The Company is engaged in co-developing four investigational products, including zimberelimab (Arcuss anti-PD-1 molecule), domvanalimab (Arcuss anti-TIGIT antibody), etrumadenant (Arcuss adenosine receptor antagonist) and quemliclustat (Arcuss CD73 inhibitor). It is engaged in pursuing a Phase II and Phase III development program for domvanalimab in combination with its anti-PD-1 antibody, zimberelimab, in multiple settings, including lung and gastrointestinal cancer.
Sector
-
More about the company

Ratings for Arcus Biosciences, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings

Consensus: Arcus Biosciences, Inc.

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
16.97 USD
Average target price
39.22 USD
Spread / Average Target
+131.13%
Consensus